Trial watch: Dendritic cell-based anticancer therapy

References

• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:17898760; http://dx.doi.org/10.1038/nature06175
   PubMed Web of Science ®Google Scholar
• Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563-604; PMID:23516985; http://dx.doi.org/10.1146/annurev-immunol-020711-074950
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto F. Ralph M. Steinman 1943-2011. Cell 2011; 147:1216-7; PMID:22263224; http://dx.doi.org/10.1016/j.cell.2011.11.040
   PubMed Web of Science ®Google Scholar
• Nussenzweig MC, Mellman I. Ralph Steinman (1943-2011). Nature 2011; 478:460; PMID:22031432; http://dx.doi.org/10.1038/478460a
   PubMed Web of Science ®Google Scholar
• Mellman I, Nussenzweig M. Retrospective. Ralph M. Steinman (1943-2011). Science 2011; 334:466; PMID:22034425; http://dx.doi.org/10.1126/science.1215136
   PubMed Web of Science ®Google Scholar
• Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142-62; PMID:4573839; http://dx.doi.org/10.1084/jem.137.5.1142
   PubMed Web of Science ®Google Scholar
• Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, Palucka AK. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003; 987:180-7; PMID:12727638; http://dx.doi.org/10.1111/j.1749-6632.2003.tb06047.x
   PubMed Web of Science ®Google Scholar
• Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O’Bar A, Agouna-Deciat O, Klucar P, Thompson-Snipes L, Zurawski S et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010; 116:1685-97; PMID:20530286; http://dx.doi.org/10.1182/blood-2010-01-264960
   PubMed Web of Science ®Google Scholar
• Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106:271-4; PMID:11509176; http://dx.doi.org/10.1016/S0092-8674(01)00448-2
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19:225-34; PMID:12932356; http://dx.doi.org/10.1016/S1074-7613(03)00208-5
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220:129-50; PMID:17979844; http://dx.doi.org/10.1111/j.1600-065X.2007.00575.x
   PubMed Web of Science ®Google Scholar
• Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, Di Pucchio T, Connolly J, Fay JW, Pascual V et al. Dendritic cell subsets in health and disease. Immunol Rev 2007; 219:118-42; PMID:17850486; http://dx.doi.org/10.1111/j.1600-065X.2007.00551.x
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pulendran B, Steinman R, Palucka K. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries? J Exp Med 2000; 192:F39-44; PMID:11120782; http://dx.doi.org/10.1084/jem.192.12.F39
   PubMed Web of Science ®Google Scholar
• Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini JC, Banchereau J, Palucka AK. Cross-priming of naive CD8+ T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192:1535-44; PMID:11104796; http://dx.doi.org/10.1084/jem.192.11.1535
   PubMed Web of Science ®Google Scholar
• Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, Zurawski S, Bosquet N, Palucka AK, Le Grand R et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med 2012; 209:109-21; PMID:22213806; http://dx.doi.org/10.1084/jem.20110399
   PubMed Web of Science ®Google Scholar
• Jotwani R, Palucka AK, Al-Quotub M, Nouri-Shirazi M, Kim J, Bell D, Banchereau J, Cutler CW. Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. J Immunol 2001; 167:4693-700; PMID:11591800; http://dx.doi.org/10.4049/jimmunol.167.8.4693
   PubMed Web of Science ®Google Scholar
• Matsui T, Connolly JE, Michnevitz M, Chaussabel D, Yu CI, Glaser C, Tindle S, Pypaert M, Freitas H, Piqueras B et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009; 182:6815-23; PMID:19454677; http://dx.doi.org/10.4049/jimmunol.0802008
   PubMed Web of Science ®Google Scholar
• Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, Palucka KA. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000; 165:3797-803; PMID:11034385; http://dx.doi.org/10.4049/jimmunol.165.7.3797
   PubMed Web of Science ®Google Scholar
• Rolland A, Guyon L, Gill M, Cai YH, Banchereau J, McClain K, Palucka AK. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol 2005; 174:3067-71; PMID:15728521; http://dx.doi.org/10.4049/jimmunol.174.5.3067
   PubMed Web of Science ®Google Scholar
• Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000; 1:510-4; PMID:11101873; http://dx.doi.org/10.1038/82763
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306; PMID:15803149; http://dx.doi.org/10.1038/nri1592
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294:1540-3; PMID:11711679; http://dx.doi.org/10.1126/science.1064890
   PubMed Web of Science ®Google Scholar
• Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science 2001; 293:253-6; PMID:11452116; http://dx.doi.org/10.1126/science.1062060
   PubMed Web of Science ®Google Scholar
• Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, Fortin A, Haniffa M, Ceron-Gutierrez L, Bacon CM et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365:127-38; PMID:21524210; http://dx.doi.org/10.1056/NEJMoa1100066
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. Taking our breath away: dendritic cells in the pathogenesis of asthma. Nat Rev Immunol 2003; 3:994-1003; PMID:14647481; http://dx.doi.org/10.1038/nri1249
   PubMed Web of Science ®Google Scholar
• Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev 2013; 254:170-89; PMID:23772620; http://dx.doi.org/10.1111/imr.12082
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Richman LP, Vonderheide RH. Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking. Oncoimmunology 2014; 3:e28610; PMID:25097801; http://dx.doi.org/10.4161/onci.28610
   PubMed Web of Science ®Google Scholar
• Sandin LC, Totterman TH, Mangsbo SM. Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer. Oncoimmunology 2014; 3:e27400; PMID:24701374; http://dx.doi.org/10.4161/onci.27400
   PubMedGoogle Scholar
• Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, Mucida D, Merad M, Steinman RM. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest 2013; 123:844-54; PMID:23298832
   PubMed Web of Science ®Google Scholar
• Watkins SK, Hurwitz AA. FOXO3: a master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology 2012; 1:252-4; PMID:22720261; http://dx.doi.org/10.4161/onci.1.2.18241
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711; PMID:12615891; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141040
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780-8; PMID:23175281; http://dx.doi.org/10.1038/nrm3479
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, Gonnella R, Frati L, Faggioni A. Activation of dendritic cells by tumor cell death. Oncoimmunology 2012; 1:1218-9; PMID:23170286; http://dx.doi.org/10.4161/onci.20428
   PubMed Web of Science ®Google Scholar
• Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, Stroncek DF. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 2010; 8:4; PMID:20078880; http://dx.doi.org/10.1186/1479-5876-8-4
   PubMed Web of Science ®Google Scholar
• Quah BJ, O’Neill HC. Maturation of function in dendritic cells for tolerance and immunity. J Cell Mol Med 2005; 9:643-54; PMID:16202211; http://dx.doi.org/10.1111/j.1582-4934.2005.tb00494.x
   PubMed Web of Science ®Google Scholar
• Nakahara T, Moroi Y, Uchi H, Furue M. Differential role of MAPK signaling in human dendritic cell maturation and Th1Th2 engagement. J Dermatol Sci 2006; 42:1-11; PMID:16352421; http://dx.doi.org/10.1016/j.jdermsci.2005.11.004
   PubMed Web of Science ®Google Scholar
• Hammer GE, Ma A. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu Rev Immunol 2013; 31:743-91; PMID:23330953; http://dx.doi.org/10.1146/annurev-immunol-020711-074929
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006; 6:476-83; PMID:16691244; http://dx.doi.org/10.1038/nri1845
   PubMed Web of Science ®Google Scholar
• Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30:1-22; PMID:22136168; http://dx.doi.org/10.1146/annurev-immunol-100311-102839
   PubMed Web of Science ®Google Scholar
• Maldonado-Lopez R, De Smedt T, Michel P, Godfroid J, Pajak B, Heirman C, Thielemans K, Leo O, Urbain J, Moser M. CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999; 189:587-92; PMID:9927520; http://dx.doi.org/10.1084/jem.189.3.587
   PubMed Web of Science ®Google Scholar
• Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maraskovsky E, Maliszewski CR. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A 1999; 96:1036-41; PMID:9927689; http://dx.doi.org/10.1073/pnas.96.3.1036
   PubMed Web of Science ®Google Scholar
• Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315:107-11; PMID:17204652; http://dx.doi.org/10.1126/science.1136080
   PubMed Web of Science ®Google Scholar
• Ueno H, Palucka AK, Banchereau J. The expanding family of dendritic cell subsets. Nat Biotechnol 2010; 28:813-5; PMID:20697407; http://dx.doi.org/10.1038/nbt0810-813
   PubMed Web of Science ®Google Scholar
• Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Banchereau J et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010; 234:199-212; PMID:20193020; http://dx.doi.org/10.1111/j.0105-2896.2009.00884.x
   PubMed Web of Science ®Google Scholar
• Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13:1145-54; PMID:23160217; http://dx.doi.org/10.1038/ni.2467
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Human dendritic cell subsets in vaccination. Curr Opin Immunol 2013; 25:396-402; PMID:23725656; http://dx.doi.org/10.1016/j.coi.2013.05.001
   PubMed Web of Science ®Google Scholar
• Klechevsky E, Banchereau J. Human dendritic cells subsets as targets and vectors for therapy. Ann N Y Acad Sci 2013; 1284:24-30; PMID:23651190; http://dx.doi.org/10.1111/nyas.12113
   PubMed Web of Science ®Google Scholar
• Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity 2014; 40:642-56; PMID:24837101; http://dx.doi.org/10.1016/j.immuni.2014.04.016
   PubMed Web of Science ®Google Scholar
• Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, Briere F, Chaussabel D, Zurawski G, Palucka AK et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29:497-510; PMID:18789730; http://dx.doi.org/10.1016/j.immuni.2008.07.013
   PubMed Web of Science ®Google Scholar
• Clausen BE, Girard-Madoux MJ. IL-10 control of dendritic cells in the skin. Oncoimmunology 2013; 2:e23186; PMID:23802070; http://dx.doi.org/10.4161/onci.23186
   PubMedGoogle Scholar
• Sere K, Felker P, Hieronymus T, Zenke M. TGFbeta1 microenvironment determines dendritic cell development. Oncoimmunology 2013; 2:e23083; PMID:23687620; http://dx.doi.org/10.4161/onci.23083
   PubMedGoogle Scholar
• Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1273-81; PMID:20479115; http://dx.doi.org/10.1084/jem.20100348
   PubMed Web of Science ®Google Scholar
• Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, Vu Manh TP, Baranek T, Storset AK, Marvel J et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1283-92; PMID:20479118; http://dx.doi.org/10.1084/jem.20100223
   PubMed Web of Science ®Google Scholar
• Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-60; PMID:20479116; http://dx.doi.org/10.1084/jem.20092140
   PubMed Web of Science ®Google Scholar
• Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1261-71; PMID:20479117; http://dx.doi.org/10.1084/jem.20092618
   PubMed Web of Science ®Google Scholar
• Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12:557-69; PMID:22790179; http://dx.doi.org/10.1038/nri3254
   PubMed Web of Science ®Google Scholar
• Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev 2010; 234:18-31; PMID:20193009; http://dx.doi.org/10.1111/j.0105-2896.2009.00870.x
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835-7; PMID:10364556; http://dx.doi.org/10.1126/science.284.5421.1835
   PubMed Web of Science ®Google Scholar
• Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1:305-10; PMID:11017101; http://dx.doi.org/10.1038/79747
   PubMed Web of Science ®Google Scholar
• Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, O'Garra A, Liu YJ. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocytemacrophage colony-stimulating factor. J Exp Med 2002; 195:953-8; PMID:11927638; http://dx.doi.org/10.1084/jem.20020045
   PubMed Web of Science ®Google Scholar
• Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ, Blazar BR, Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173:4433-42; PMID:15383574; http://dx.doi.org/10.4049/jimmunol.173.7.4433
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
   PubMed Web of Science ®Google Scholar
• Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209:495-506; PMID:22351930; http://dx.doi.org/10.1084/jem.20111413
   PubMed Web of Science ®Google Scholar
• Tomihara K, Guo M, Shin T, Sun X, Ludwig SM, Brumlik MJ, Zhang B, Curiel TJ, Shin T. Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J Immunol 2010; 184:6151-60; PMID:20427766; http://dx.doi.org/10.4049/jimmunol.0903519
   PubMed Web of Science ®Google Scholar
• Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008; 27:5920-31; PMID:18836473; http://dx.doi.org/10.1038/onc.2008.270
   PubMed Web of Science ®Google Scholar
• Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12:214-9; PMID:16444265; http://dx.doi.org/10.1038/nm1356
   PubMed Web of Science ®Google Scholar
• Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j.immuni.2013.03.003
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922
   PubMed Web of Science ®Google Scholar
• Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347
   PubMed Web of Science ®Google Scholar
• Noessner E, Brech D, Mendler AN, Masouris I, Schlenker R, Prinz PU. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012; 1:1451-3; PMID:23243626; http://dx.doi.org/10.4161/onci.21356
   PubMed Web of Science ®Google Scholar
• Sisirak V, Faget J, Vey N, Blay JY, Menetrier-Caux C, Caux C, Bendriss-Vermare N. Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3 regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology 2013; 2:e22338; PMID:23482834; http://dx.doi.org/10.4161/onci.22338
   PubMedGoogle Scholar
• Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/onci.22009
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:23170259; http://dx.doi.org/10.4161/onci.21494
   PubMed Web of Science ®Google Scholar
• Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001; 91:2136-47; PMID:11391595; http://dx.doi.org/10.1002/1097-0142(20010601)91:11%3c2136::AID-CNCR1242%3e3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Ikeguchi M, Ikeda M, Tatebe S, Maeta M, Kaibara N. Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 1998; 5:1185-9; PMID:9683832
   PubMed Web of Science ®Google Scholar
• Ishigami S, Natsugoe S, Matsumoto M, Okumura H, Sakita H, Nakashima S, Takao S, Aikou T. Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 2003; 10:1237-40; PMID:12883687
   PubMed Web of Science ®Google Scholar
• Kakeji Y, Maehara Y, Korenaga D, Tsujitani S, Haraguchi M, Watanabe A, Orita H, Sugimachi K. Prognostic significance of tumor-host interaction in clinical gastric cancer: relationship between DNA ploidy and dendritic cell infiltration. J Surg Oncol 1993; 52:207-12; PMID:8468980; http://dx.doi.org/10.1002/jso.2930520402
   PubMed Web of Science ®Google Scholar
• Ishigami S, Aikou T, Natsugoe S, Hokita S, Iwashige H, Tokushige M, Sonoda S. Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology 1998; 55:65-9; PMID:9428378; http://dx.doi.org/10.1159/000011837
   PubMed Web of Science ®Google Scholar
• Okuyama T, Maehara Y, Kakeji Y, Tsuijitani S, Korenaga D, Sugimachi K. Interrelation between tumor-associated cell surface glycoprotein and host immune response in gastric carcinoma patients. Cancer 1998; 82:1468-75; PMID:9554522; http://dx.doi.org/10.1002/(SICI)1097-0142(19980415)82:8%3c1468::AID-CNCR6%3e3.0.CO;2-5
   PubMedGoogle Scholar
• Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, Aridome K, Hokita S, Aikou T. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000; 159:103-8; PMID:10974412; http://dx.doi.org/10.1016/S0304-3835(00)00542-5
   PubMed Web of Science ®Google Scholar
• Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Ohro S, Tatebe S, Tsujitani S, Ikeguchi M. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007; 95:123-8; PMID:17262742; http://dx.doi.org/10.1002/jso.20612
   PubMed Web of Science ®Google Scholar
• Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol 2008; 26:3235-41; PMID:18591558; http://dx.doi.org/10.1200/JCO.2007.13.9048
   PubMed Web of Science ®Google Scholar
• Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J, Tang ZY. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132:293-301; PMID:16421755; http://dx.doi.org/10.1007/s00432-006-0075-y
   PubMed Web of Science ®Google Scholar
• Yin XY, Lu MD, Lai YR, Liang LJ, Huang JF. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 2003; 50:1281-4; PMID:14571719
   PubMed Web of Science ®Google Scholar
• Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, Hiraoka K, Itoh T, Kondo S, Katoh H. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003; 89:1736-42; PMID:14583778; http://dx.doi.org/10.1038/sj.bjc.6601331
   PubMed Web of Science ®Google Scholar
• Honig A, Schaller N, Dietl J, Backe J, Kammerer U. S100 as an immunohistochemically-detected marker with prognostic significance in endometrial carcinoma. Anticancer Res 2005; 25:1747-53; PMID:16033094
   PubMed Web of Science ®Google Scholar
• Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 2007; 13:6666-72; PMID:18006767; http://dx.doi.org/10.1158/1078-0432.CCR-07-0504
   PubMed Web of Science ®Google Scholar
• Furihata M, Ohtsuki Y, Sonobe H, Araki K, Ogata T, Toki T, Ogoshi S, Tamiya T. Prognostic significance of simultaneous infiltration of HLA-DR-positive dendritic cells and tumor infiltrating lymphocytes into human esophageal carcinoma. Tohoku J Exp Med 1993; 169:187-95; PMID:8248911; http://dx.doi.org/10.1620/tjem.169.187
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, Gon G, Toyoda M, Tanigawa N. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003; 104:92-7; PMID:12532424; http://dx.doi.org/10.1002/ijc.10915
   PubMed Web of Science ®Google Scholar
• Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx.doi.org/10.1200/JCO.2007.15.0284
   PubMed Web of Science ®Google Scholar
• Sautes-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, Dieu-Nosjean MC. Tumor microenvironment is multifaceted. Cancer Metastasis Rev 2011; 30:13-25; PMID:21271351; http://dx.doi.org/10.1007/s10555-011-9279-y
   PubMed Web of Science ®Google Scholar
• Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, Gaudi I, Tímár J. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007; 56:1459-69; PMID:17279413; http://dx.doi.org/10.1007/s00262-007-0286-3
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Suzuki K, Yashi M, Yuzawa M, Takayashiki N, Morita T. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res 2007; 27:1137-41; PMID:17465253
   PubMed Web of Science ®Google Scholar
• Conrad C, Gilliet M. Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: a dangerous liaison. Oncoimmunology 2013; 2:e23887; PMID:23762788; http://dx.doi.org/10.4161/onci.23887
   PubMed Web of Science ®Google Scholar
• Ishigami S, Ueno S, Matsumoto M, Okumura H, Arigami T, Uchikado Y, Setoyama T, Arima H, Sasaki K, Kitazono M et al. Prognostic value of CD208-positive cell infiltration in gastric cancer. Cancer Immunol Immunother 2010; 59:389-95; PMID:19760221; http://dx.doi.org/10.1007/s00262-009-0758-8
   PubMed Web of Science ®Google Scholar
• Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn CM, Ensink NG, Tollenaar RA et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005; 11:2576-82; PMID:15814636; http://dx.doi.org/10.1158/1078-0432.CCR-04-1448
   PubMed Web of Science ®Google Scholar
• Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466-74; PMID:15569976; http://dx.doi.org/10.1158/1078-0432.CCR-04-0684
   PubMed Web of Science ®Google Scholar
• Jensen TO, Schmidt H, Moller HJ, Donskov F, Hoyer M, Sjoegren P, Christensen IJ, Steiniche T. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage III melanoma. Cancer 2012; 118:2476-85; PMID:21953023; http://dx.doi.org/10.1002/cncr.26511
   PubMedGoogle Scholar
• Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, Caux C, Bendriss-Vermare N. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology 2012; 1:380-2; PMID:22737622; http://dx.doi.org/10.4161/onci.18801
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Targeting dendritic cell metabolism in cancer. Nat Med 2010; 16:858-9; PMID:20689548; http://dx.doi.org/10.1038/nm0810-858
   PubMed Web of Science ®Google Scholar
• Lombardi V, Akbari O. Dendritic cell modulation as a new interventional approach for the treatment of asthma. Drug News Perspect 2009; 22:445-51; PMID:20016853
   PubMed Web of Science ®Google Scholar
• Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305:200-5; PMID:15247469; http://dx.doi.org/10.1126/science.1100369
   PubMed Web of Science ®Google Scholar
• Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80; PMID:15122249; http://dx.doi.org/10.1038/nm1039
   PubMed Web of Science ®Google Scholar
• Nabel GJ. Designing tomorrow's vaccines. N Engl J Med 2013; 368:551-60; PMID:23388006; http://dx.doi.org/10.1056/NEJMra1204186
   PubMed Web of Science ®Google Scholar
• Gross CC, Wiendl H. Dendritic cell vaccination in autoimmune disease. Curr Opin Rheumatol 2013; 25:268-74; PMID:23370378; http://dx.doi.org/10.1097/BOR.0b013e32835cb9f2
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-67; PMID:24872109; http://dx.doi.org/10.1016/S1470-2045(13)70585-0
   PubMed Web of Science ®Google Scholar
• Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-203; PMID:17476349; http://dx.doi.org/10.1172/JCI31205
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802; PMID:17853902; http://dx.doi.org/10.1038/nri2173
   PubMed Web of Science ®Google Scholar
• Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Herberman RB, Lotze MT et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2:337-49; PMID:12440225; http://dx.doi.org/10.1046/j.1359-4117.2002.01050.x
   PubMedGoogle Scholar
• Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999; 59:4035-41; PMID:10463604
   PubMed Web of Science ®Google Scholar
• Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004; 10:2891-901; PMID:15102698; http://dx.doi.org/10.1158/1078-0432.CCR-03-0380
   PubMed Web of Science ®Google Scholar
• Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, Black KL, Yu JS. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006; 66:8887-96; PMID:16951206; http://dx.doi.org/10.1158/0008-5472.CAN-05-3448
   PubMed Web of Science ®Google Scholar
• Endo H, Saito T, Kenjo A, Hoshino M, Terashima M, Sato T, Anazawa T, Kimura T, Tsuchiya T, Irisawa A et al. Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. J Hepatobiliary Pancreat Sci 2012; 19:465-75; PMID:21983893; http://dx.doi.org/10.1007/s00534-011-0457-7
   PubMed Web of Science ®Google Scholar
• You CX, Shi M, Liu Y, Cao M, Luo R, Hermonat PL. AAV2IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: evidence for IL-12 intracrine activity in DC. Oncoimmunology 2012; 1:847-55; PMID:23162752; http://dx.doi.org/10.4161/onci.20504
   PubMed Web of Science ®Google Scholar
• Bol KF, Tel J, de Vries IJ, Figdor CG. Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology 2013; 2:e23431; PMID:23802086; http://dx.doi.org/10.4161/onci.23431
   PubMedGoogle Scholar
• Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70:706-15; PMID:9096653; http://dx.doi.org/10.1002/(SICI)1097-0215(19970317)70:6%3c706::AID-IJC13%3e3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D, Seigler H. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 1998; 68:79-91; PMID:9624036; http://dx.doi.org/10.1002/(SICI)1096-9098(199806)68:2%3c79::AID-JSO3%3e3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 1998; 185:65-74; PMID:9636684; http://dx.doi.org/10.1006/cimm.1998.1277
   PubMed Web of Science ®Google Scholar
• Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998; 95:9482-7; PMID:9689106; http://dx.doi.org/10.1073/pnas.95.16.9482
   PubMed Web of Science ®Google Scholar
• Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptoticnecrotic tumor cells. Int J Cancer 2001; 93:539-48; PMID:11477558; http://dx.doi.org/10.1002/ijc.1365
   PubMed Web of Science ®Google Scholar
• Paczesny S, Beranger S, Salzmann JL, Klatzmann D, Colombo BM. Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells. Cancer Res 2001; 61:2386-9; PMID:11289101
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Choudhury A, Mahdian R, Lundin J, Moshfegh A, Osterborg A, Mellstedt H. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004; 18:1810-5; PMID:15385926; http://dx.doi.org/10.1038/sj.leu.2403517
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Rezvany MR, Virving L, Choudhury A, Rabbani H, Osterborg A, Mellstedt H. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 2003; 17:894-9; PMID:12750703; http://dx.doi.org/10.1038/sj.leu.2402913
   PubMed Web of Science ®Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-9; PMID:9510252; http://dx.doi.org/10.1038/32183
   PubMed Web of Science ®Google Scholar
• Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359-68; PMID:9763615; http://dx.doi.org/10.1084/jem.188.7.1359
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-302; PMID:7489412; http://dx.doi.org/10.1038/nm1295-1297
   PubMed Web of Science ®Google Scholar
• Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18:86-94; PMID:8574470; http://dx.doi.org/10.1097/00002371-199508000-00002
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183:1357-65; PMID:8666894; http://dx.doi.org/10.1084/jem.183.4.1357
   PubMed Web of Science ®Google Scholar
• Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183:317-22; PMID:8551239; http://dx.doi.org/10.1084/jem.183.1.317
   PubMed Web of Science ®Google Scholar
• Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ, Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998; 161:2094-8; PMID:9725199
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183:87-97; PMID:8551248; http://dx.doi.org/10.1084/jem.183.1.87
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, Lotze MT. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15:94-103; PMID:9090785; http://dx.doi.org/10.1002/stem.150094
   PubMed Web of Science ®Google Scholar
• Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5:405-11; PMID:10202929; http://dx.doi.org/10.1038/7403
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465-72; PMID:8760800; http://dx.doi.org/10.1084/jem.184.2.465
   PubMed Web of Science ®Google Scholar
• Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186:1177-82; PMID:9314567; http://dx.doi.org/10.1084/jem.186.7.1177
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34; PMID:10706120
   PubMed Web of Science ®Google Scholar
• Irvine AS, Trinder PK, Laughton DL, Ketteringham H, McDermott RH, Reid SC, Haines AM, Amir A, Husain R, Doshi R, et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat Biotechnol 2000; 18:1273-8; PMID:11101806; http://dx.doi.org/10.1038/82383
   PubMed Web of Science ®Google Scholar
• Manickan E, Kanangat S, Rouse RJ, Yu Z, Rouse BT. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 1997; 61:125-32; PMID:9021916
   PubMed Web of Science ®Google Scholar
• Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal RG. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186:1247-56; PMID:9334364; http://dx.doi.org/10.1084/jem.186.8.1247
   PubMed Web of Science ®Google Scholar
• Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or “self” antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27:2702-7; PMID:9368629; http://dx.doi.org/10.1002/eji.1830271033
   PubMed Web of Science ®Google Scholar
• Wan Y, Bramson J, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8:1355-63; PMID:9295130; http://dx.doi.org/10.1089/hum.1997.8.11-1355
   PubMed Web of Science ®Google Scholar
• McArthur JG, Mulligan RC. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 1998; 21:41-7; PMID:9456435; http://dx.doi.org/10.1097/00002371-199801000-00005
   PubMed Web of Science ®Google Scholar
• Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, Carbone DP. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999; 117:244-51; PMID:10444254; http://dx.doi.org/10.1046/j.1365-2249.1999.00913.x
   PubMed Web of Science ®Google Scholar
• Tuting T, Steitz J, Bruck J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J Gene Med 1999; 1:400-6; PMID:10753065; http://dx.doi.org/10.1002/(SICI)1521-2254(199911/12)1:6%3c400::AID-JGM68%3e3.0.CO;2-D
   PubMedGoogle Scholar
• Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, Gauldie J. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999; 198:131-8; PMID:10648127; http://dx.doi.org/10.1006/cimm.1999.1585
   PubMed Web of Science ®Google Scholar
• Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000; 191:1699-708; PMID:10811863; http://dx.doi.org/10.1084/jem.191.10.1699
   PubMed Web of Science ®Google Scholar
• Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, Amarnani SN, Glaspy JA, McBride WH, Economou JS. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000; 23:59-66; PMID:10687138; http://dx.doi.org/10.1097/00002371-200001000-00008
   PubMed Web of Science ®Google Scholar
• Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, Mizuguchi H, Mori K, Okada Y, Fujita T, Hayakawa T et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61:7913-9; PMID:11691812
   PubMed Web of Science ®Google Scholar
• Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000; 165:5713-9; PMID:11067929; http://dx.doi.org/10.4049/jimmunol.165.10.5713
   PubMed Web of Science ®Google Scholar
• Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011-7; PMID:10973321; http://dx.doi.org/10.1038/79519
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 2001; 94:474-81; PMID:11235953; http://dx.doi.org/10.3171/jns.2001.94.3.0474
   PubMed Web of Science ®Google Scholar
• Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002; 22:613-21; PMID:12014629
   PubMed Web of Science ®Google Scholar
• Van Meirvenne S, Straetman L, Heirman C, Dullaers M, De Greef C, Van Tendeloo V, Thielemans K. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002; 9:787-97; PMID:12189529; http://dx.doi.org/10.1038/sj.cgt.7700499
   PubMedGoogle Scholar
• Li M, You S, Ge W, Ma S, Ma N, Zhao C. Induction of T-cell immunity against leukemia by dendritic cells pulsed with total RNA isolated from leukemia cells. Chin Med J (Engl) 2003; 116:1655-61; PMID:14642130
   PubMed Web of Science ®Google Scholar
• Minami T, Nakanishi Y, Izumi M, Harada T, Hara N. Enhancement of antigen-presenting capacity and antitumor immunity of dendritic cells pulsed with autologous tumor-derived RNA in mice. J Immunother 2003; 26:420-31; PMID:12973031; http://dx.doi.org/10.1097/00002371-200309000-00005
   PubMed Web of Science ®Google Scholar
• Schmidt T, Ziske C, Marten A, Endres S, Tiemann K, Schmitz V, Gorschlüter M, Schneider C, Sauerbruch T, Schmidt-Wolf IG. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL6 pancreatic murine tumor model. Cancer Res 2003; 63:8962-7; PMID:14695214
   PubMed Web of Science ®Google Scholar
• Jung CW, Kwon JH, Seol JG, Park WH, Hyun JM, Kim ES, Kim ST, Lee SJ, Kim BK, Lee YY. Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA. Am J Hematol 2004; 75:121-7; PMID:14978690; http://dx.doi.org/10.1002/ajh.10471
   PubMed Web of Science ®Google Scholar
• Liu BY, Chen XH, Gu QL, Li JF, Yin HR, Zhu ZG, Lin YZ. Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer. World J Gastroenterol 2004; 10:630-3; PMID:14991927
   PubMed Web of Science ®Google Scholar
• Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003; 170:5391-7; PMID:12759413; http://dx.doi.org/10.4049/jimmunol.170.11.5391
   PubMed Web of Science ®Google Scholar
• Celluzzi CM, Falo LD, Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160:3081-5; PMID:9531260
   PubMed Web of Science ®Google Scholar
• Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161:5516-24; PMID:9820528
   PubMed Web of Science ®Google Scholar
• Tanaka H, Shimizu K, Hayashi T, Shu S. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 2002; 220:1-12; PMID:12718934; http://dx.doi.org/10.1016/S0008-8749(03)00009-1
   PubMed Web of Science ®Google Scholar
• Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 2001; 213:4-13; PMID:11747351; http://dx.doi.org/10.1006/cimm.2001.1864
   PubMed Web of Science ®Google Scholar
• Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003; 225:65-74; PMID:14698141; http://dx.doi.org/10.1016/j.cellimm.2003.09.005
   PubMed Web of Science ®Google Scholar
• Sukhorukov VL, Reuss R, Endter JM, Fehrmann S, Katsen-Globa A, Gessner P, Steinbach A, Müller KJ, Karpas A, Zimmermann U et al. A biophysical approach to the optimisation of dendritic-tumour cell electrofusion. Biochem Biophys Res Commun 2006; 346:829-39; PMID:16780801; http://dx.doi.org/10.1016/j.bbrc.2006.05.193
   PubMed Web of Science ®Google Scholar
• Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labbe J, Bonnotte B. Dendritic cell-tumor cell hybrids and immunotherapy: what's next? Cytotherapy 2011; 13:774-85; PMID:21299362; http://dx.doi.org/10.3109/14653249.2011.553593
   PubMed Web of Science ®Google Scholar
• Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M, O'Donnell D, Selby P, Vile R, Melcher A. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 2006; 13:138-49; PMID:16136162; http://dx.doi.org/10.1038/sj.gt.3302609
   PubMed Web of Science ®Google Scholar
• Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:15024047; http://dx.doi.org/10.1084/jem.20032220
   PubMed Web of Science ®Google Scholar
• Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196:1627-38; PMID:12486105; http://dx.doi.org/10.1084/jem.20021598
   PubMed Web of Science ®Google Scholar
• Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194:769-79; PMID:11560993; http://dx.doi.org/10.1084/jem.194.6.769
   PubMed Web of Science ®Google Scholar
• Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P et al. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007; 179:3371-9; PMID:17709554; http://dx.doi.org/10.4049/jimmunol.179.5.3371
   PubMed Web of Science ®Google Scholar
• Berraondo P, Nouze C, Preville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007; 67:8847-55; PMID:17875726; http://dx.doi.org/10.1158/0008-5472.CAN-07-0321
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106:1278-85; PMID:15878980; http://dx.doi.org/10.1182/blood-2005-01-0318
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 2012; 33:4229-39; PMID:22410170; http://dx.doi.org/10.1016/j.biomaterials.2012.02.036
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 2012; 119:2284-92; PMID:22234694; http://dx.doi.org/10.1182/blood-2011-08-373944
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, Figdor CG, Cambi A. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 2011; 118:4111-9; PMID:21860028; http://dx.doi.org/10.1182/blood-2011-04-346957
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Ter Huurne M, Torensma R, Figdor CG. Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking. Eur J Immunol 2012; 42:1989-98; PMID:22653683; http://dx.doi.org/10.1002/eji.201142258
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, Lambeck AJ, Figdor CG. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118:6836-44; PMID:21967977; http://dx.doi.org/10.1182/blood-2011-07-367615
   PubMed Web of Science ®Google Scholar
• Wang B. Targeting dendritic cells in situ for breast cancer immunotherapy. Oncoimmunology 2012; 1:1398-400; PMID:23243606; http://dx.doi.org/10.4161/onci.20982
   PubMed Web of Science ®Google Scholar
• Garcia-Vallejo JJ, Unger WW, Kalay H, van Kooyk Y. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. Oncoimmunology 2013; 2:e23040; PMID:23525136; http://dx.doi.org/10.4161/onci.23040
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4:594-600; PMID:9585234; http://dx.doi.org/10.1038/nm0598-594
   PubMed Web of Science ®Google Scholar
• Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999; 147:599-610; PMID:10545503; http://dx.doi.org/10.1083/jcb.147.3.599
   PubMed Web of Science ®Google Scholar
• Viaud S, Thery C, Ploix S, Tursz T, Lapierre V, Lantz O, Zitvogel L, Chaput N. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res 2010; 70:1281-5; PMID:20145139; http://dx.doi.org/10.1158/0008-5472.CAN-09-3276
   PubMed Web of Science ®Google Scholar
• Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012; 1:1074-83; PMID:23170255; http://dx.doi.org/10.4161/onci.20897
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013; 2:e22664; PMID:23482679; http://dx.doi.org/10.4161/onci.22664
   PubMed Web of Science ®Google Scholar
• Fucikova J, Rozkova D, Ulcova H, Budinsky V, Sochorova K, Pokorna K, Bartůňková J, Špíšek R. Poly I: c-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med 2011; 9:223; PMID:22208910; http://dx.doi.org/10.1186/1479-5876-9-223
   PubMed Web of Science ®Google Scholar
• Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, Spísek R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71:4821-33; PMID:21602432; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950
   PubMed Web of Science ®Google Scholar
• Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008; 31:101-12; PMID:18157017; http://dx.doi.org/10.1097/CJI.0b013e318159f5ba
   PubMed Web of Science ®Google Scholar
• Lee J, Boczkowski D, Nair S. Programming human dendritic cells with mRNA. Methods Mol Biol 2013; 969:111-25; PMID:23296931; http://dx.doi.org/10.1007/978-1-62703-260-5_8
   PubMedGoogle Scholar
• Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, Vujanovic L, Kirkwood JM, Butterfield LH. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology 2012; 1:287-357; PMID:22737604; http://dx.doi.org/10.4161/onci.18628
   PubMed Web of Science ®Google Scholar
• Garg NK, Dwivedi P, Prabha P, Tyagi RK. RNA pulsed dendritic cells: an approach for cancer immunotherapy. Vaccine 2013; 31:1141-56; PMID:23306369; http://dx.doi.org/10.1016/j.vaccine.2012.12.027
   PubMed Web of Science ®Google Scholar
• Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H et al. Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology 2013; 2:e24437; PMID:23762810; http://dx.doi.org/10.4161/onci.24437
   PubMedGoogle Scholar
• Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv 2013; 2013:869718; PMID:24228179; http://dx.doi.org/10.1155/2013/869718
   PubMedGoogle Scholar
• Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, Freyburger L, Eppolito C, Sapoznikov A, Amessou M, Quintin-Colonna F et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 2006; 36:1124-35; PMID:16568496; http://dx.doi.org/10.1002/eji.200535443
   PubMed Web of Science ®Google Scholar
• Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amigorena S, Ricciardi-Castagnoli P et al. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol 2000; 165:3301-8; PMID:10975847; http://dx.doi.org/10.4049/jimmunol.165.6.3301
   PubMed Web of Science ®Google Scholar
• Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, Tyler PC, Davies NM. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21:883-90; PMID:12547598; http://dx.doi.org/10.1016/S0264-410X(02)00536-4
   PubMed Web of Science ®Google Scholar
• van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004; 64:4357-65; PMID:15205352; http://dx.doi.org/10.1158/0008-5472.CAN-04-0138
   PubMed Web of Science ®Google Scholar
• Badiee A, Davies N, McDonald K, Radford K, Michiue H, Hart D, Kato M. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 2007; 25:4757-66; PMID:17512099; http://dx.doi.org/10.1016/j.vaccine.2007.04.029
   PubMed Web of Science ®Google Scholar
• Yang L, Yang H, Rideout K, Cho T, Joo KI, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008; 26:326-34; PMID:18297056; http://dx.doi.org/10.1038/nbt1390
   PubMed Web of Science ®Google Scholar
• Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tuting T, van den Eertwegh AJ, Gerritsen WR, van Beusechem VW, Pereboev A, Curiel DT et al. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Res 2011; 71:5827-37; PMID:21747119; http://dx.doi.org/10.1158/0008-5472.CAN-11-0804
   PubMed Web of Science ®Google Scholar
• Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, Timares L, Korokhov N, O'Neill AM, de Gruijl TD et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009; 27:7116-24; PMID:19786146; http://dx.doi.org/10.1016/j.vaccine.2009.09.055
   PubMed Web of Science ®Google Scholar
• Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ, Curiel DT. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol Ther 2005; 4:289-94; PMID:15753654; http://dx.doi.org/10.4161/cbt.4.3.1499
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi.org/10.4161/onci.20696
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G et al. Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3:e29179; PMID:25083332; http://dx.doi.org/10.4161/onci.29179
   PubMedGoogle Scholar
• Duluc D, Joo H, Ni L, Yin W, Upchurch K, Li D, Xue Y, Klucar P, Zurawski S, Zurawski G et al. Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1. J Immunol 2014; 192:5776-88; PMID:24835401; http://dx.doi.org/10.4049/jimmunol.1301661
   PubMed Web of Science ®Google Scholar
• Yu CI, Becker C, Wang Y, Marches F, Helft J, Leboeuf M, Anguiano E, Pourpe S, Goller K, Pascual V et al. Human CD1c +dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-beta. Immunity 2013; 38:818-30; PMID:23562160; http://dx.doi.org/10.1016/j.immuni.2013.03.004
   PubMed Web of Science ®Google Scholar
• Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G et al. Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5:172ra20; PMID:23408053; http://dx.doi.org/10.1126/scitranslmed.3004888
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fucikova J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; PMID:24286020; http://dx.doi.org/10.4161/onci.25771
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW. Sipuleucel-T. Nat Rev Drug Discov 2010; 9:513-4; PMID:20592741; http://dx.doi.org/10.1038/nrd3220
   PubMed Web of Science ®Google Scholar
• Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17:3520-6; PMID:21471425; http://dx.doi.org/10.1158/1078-0432.CCR-10-3126
   PubMed Web of Science ®Google Scholar
• Galluzzi L. New immunotherapeutic paradigms for castration-resistant prostate cancer. Oncoimmunology 2013; 3:e26084; http://dx.doi.org/10.4161/onci.26084
   Google Scholar
• Qiu Y, Yun MM, Xu MB, Wang YZ, Yun S. Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study. Int J Clin Oncol 2013; 18:657-65; PMID:22847800; http://dx.doi.org/10.1007/s10147-012-0434-4
   PubMed Web of Science ®Google Scholar
• Abediankenari S, Janbabaei Mollae G, Ghasemi M, Yousefzadeh Y, Bahrami M, Alimoghaddam K. Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells. Acta Med Iran 2013; 51:284-8; PMID:23737309
   PubMedGoogle Scholar
• Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, Fisher C, Tchou J, Fox K, Zhang P et al. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS. Ann Surg Oncol 2013; 20:3233-9; PMID:23851609; http://dx.doi.org/10.1245/s10434-013-3119-y
   PubMed Web of Science ®Google Scholar
• Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013; 123:3383-94; PMID:23867552; http://dx.doi.org/10.1172/JCI68395
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, Yanagida E, Shibamoto Y, Ogasawara M, Tsujitani S et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg 2013; 17:1609-17; PMID:23877328; http://dx.doi.org/10.1007/s11605-013-2286-2
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014; 20:2433-44; PMID:24583792; http://dx.doi.org/10.1158/1078-0432.CCR-13-2617
   PubMed Web of Science ®Google Scholar
• Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 2014; 20:2457-65; PMID:24634374; http://dx.doi.org/10.1158/1078-0432.CCR-13-3017
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, Tanii M, Okamoto M, Tsujitani S, Yusa S et al. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother 2014; 63:797-806; PMID:24777613; http://dx.doi.org/10.1007/s00262-014-1554-7
   PubMedGoogle Scholar
• Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Koido S, Homma S, Okamoto M, Takakura K et al. Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms’ Tumor 1 (WT1)-Specific MHC Class III-Restricted Epitopes for Pancreatic Cancer. Clin Cancer Res 2014; 20:4228-39; PMID:25056373; http://dx.doi.org/10.1158/1078-0432.CCR-14-0314
   PubMed Web of Science ®Google Scholar
• Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 2014; 3:e27589; PMID:24734217; http://dx.doi.org/10.4161/onci.27589
   PubMed Web of Science ®Google Scholar
• Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. J Transl Med 2013; 11:135; PMID:23725550; http://dx.doi.org/10.1186/1479-5876-11-135
   PubMed Web of Science ®Google Scholar
• Reyes D, Salazar L, Espinoza E, Pereda C, Castellon E, Valdevenito R, Huidobro C, Inés Becker M, Lladser A, López MN et al. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br J Cancer 2013; 109:1488-97; PMID:23989944; http://dx.doi.org/10.1038/bjc.2013.494
   PubMed Web of Science ®Google Scholar
• Bapsy PP, Sharan B, Kumar C, Das RP, Rangarajan B, Jain M, Suresh Attili VS, Subramanian S, Aggarwal S, Srivastava M et al. Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Cytotherapy 2014; 16:234-44; PMID:24438902; http://dx.doi.org/10.1016/j.jcyt.2013.11.013
   PubMed Web of Science ®Google Scholar
• Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, Liu HC, Alexandrou AT, Jones J, Zhao R et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One 2014; 9:e93886; PMID:24699863; http://dx.doi.org/10.1371/journal.pone.0093886
   PubMed Web of Science ®Google Scholar
• Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W et al. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. J Immunother Cancer 2014; 2:4; PMID:24829761; http://dx.doi.org/10.1186/2051-1426-2-4
   PubMedGoogle Scholar
• Baek S, Kim YM, Kim SB, Kim CS, Kwon SW, Kim Y, Kim H, Lee H. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase III trial. Cell Mol Immunol 2014; PMID:24976269; http://dx.doi.org/10.1038/cmi.2014.40
   PubMedGoogle Scholar
• Poschke I, Lovgren T, Adamson L, Nystrom M, Andersson E, Hansson J, Tell R, Masucci GV, Kiessling R. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother 2014; 63:1061-71; PMID:24993563; http://dx.doi.org/10.1007/s00262-014-1575-2
   PubMed Web of Science ®Google Scholar
• Ramanathan P, Ganeshrajah S, Raghanvan RK, Singh SS, Thangarajan R. Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer - a feasibility study. Asian Pac J Cancer Prev 2014; 15:5909-16; PMID:25081721; http://dx.doi.org/10.7314/APJCP.2014.15.4.1633
   PubMedGoogle Scholar
• de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V et al. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy andor preleukapheresis IFN-alpha in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study. J Transl Med 2014; 12:209; PMID:25053129; http://dx.doi.org/10.1186/1479-5876-12-209
   PubMedGoogle Scholar
• Shimizu K, Kotera Y, Aruga A, Takeshita N, Katagiri S, Ariizumi S, Takahashi Y, Yoshitoshi K, Takasaki K, Yamamoto M. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum Vaccin Immunother 2014; 10:970-6; PMID:24419174; http://dx.doi.org/10.4161/hv.27678
   PubMed Web of Science ®Google Scholar
• Hunyadi J, Andras C, Szabo I, Szanto J, Szluha K, Sipka S, Kovács P, Kiss A, Szegedi G, Altorjay I et al. Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-a phase I-II study. Pathol Oncol Res 2013; PMID:24163303
   PubMedGoogle Scholar
• Shibamoto Y, Okamoto M, Kobayashi M, Ayakawa S, Iwata H, Sugie C, Mitsuishi Y, Takahashi H. Immune-maximizing (IMAX) therapy for cancer: combination of dendritic cell vaccine and intensity-modulated radiation. Mol Clin Oncol 2013; 1:649-54; PMID:24649223
   PubMedGoogle Scholar
• Everson RG, Jin RM, Wang X, Safaee M, Scharnweber R, Lisiero DN, Soto H, Liau LM, Prins RM. Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer 2014; 2:10; PMID:24883189; http://dx.doi.org/10.1186/2051-1426-2-10
   PubMedGoogle Scholar
• Ng L, Heck W, Lavsa S, Crowther D, Atkinson B, Xiao L, Araujo J. The lack of predictors for rapid progression in prostate cancer patients receiving sipuleucel-T. Cancers (Basel) 2013; 5:511-8; PMID:24216988; http://dx.doi.org/10.3390/cancers5020511
   PubMedGoogle Scholar
• Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B et al. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother 2013; 62:1381-92; PMID:23728352; http://dx.doi.org/10.1007/s00262-013-1438-2
   PubMed Web of Science ®Google Scholar
• Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, Vergote I, Amant F, Van Gool SW. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Res 2013; 33:3855-9; PMID:24023319
   PubMed Web of Science ®Google Scholar
• Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, VAN Gool SW. Wilms’ Tumor Gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase III clinical trial. Anticancer Res 2013; 33:5495-500; PMID:24324087
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang B, Gao H, Ding G, Wu Q, Zhang J, Liao L, Chen H. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer 2014; 14:251; PMID:24720900; http://dx.doi.org/10.1186/1471-2407-14-251
   PubMed Web of Science ®Google Scholar
• Shindo Y, Hazama S, Maeda Y, Matsui H, Iida M, Suzuki N, Yoshimura K, Ueno T, Yoshino S, Sakai K et al. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. J Transl Med 2014; 12:175; PMID:24947606; http://dx.doi.org/10.1186/1479-5876-12-175
   PubMed Web of Science ®Google Scholar
• Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tonnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62:1499-509; PMID:23817721; http://dx.doi.org/10.1007/s00262-013-1453-3
   PubMed Web of Science ®Google Scholar
• Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int 2013; 2013:976383; PMID:23509826; http://dx.doi.org/10.1155/2013/976383
   PubMedGoogle Scholar
• Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 2013; 24:2686-93; PMID:23904461; http://dx.doi.org/10.1093/annonc/mdt245
   PubMed Web of Science ®Google Scholar
• Ren J, Di L, Song G, Yu J, Jia J, Zhu Y, Yan Y, Jiang H, Liang X, Che L et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol 2013; 15:780-8; PMID:23359185; http://dx.doi.org/10.1007/s12094-013-1001-9
   PubMed Web of Science ®Google Scholar
• Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 2014; 35:987-94; PMID:24006222; http://dx.doi.org/10.1007/s13277-013-1132-1
   PubMed Web of Science ®Google Scholar
• Cui Y, Yang X, Zhu W, Li J, Wu X, Pang Y. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol Lett 2013; 6:537-41; PMID:24137363
   PubMed Web of Science ®Google Scholar
• Wang ZX, Cao JX, Wang M, Li D, Cui YX, Zhang XY, Liu JL, Li JL. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy 2014; 16:934-45; PMID:24794183; http://dx.doi.org/10.1016/j.jcyt.2014.02.011
   PubMed Web of Science ®Google Scholar
• Hasumi K, Aoki Y, Wantanabe R, Mann DL. Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy. Oncoimmunology 2013; 2:e26381; PMID:24349874; http://dx.doi.org/10.4161/onci.26381
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6:232ra51; PMID:24739759; http://dx.doi.org/10.1126/scitranslmed.3008068
   PubMed Web of Science ®Google Scholar
• Vassilaros S, Tsibanis A, Tsikkinis A, Pietersz GA, McKenzie IF, Apostolopoulos V. Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy 2013; 5:1177-82; PMID:24188672; http://dx.doi.org/10.2217/imt.13.126
   PubMed Web of Science ®Google Scholar
• Ho VT, Kim HT, Kao G, Cutler C, Levine J, Rosenblatt J, Joyce R, Antin JH, Soiffer RJ, Ritz J et al. Sequential infusion of donor derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2014; 89:1092-6; PMID:25132538; http://dx.doi.org/10.1002/ajh.23825
   PubMedGoogle Scholar
• Takeda T, Takeda T, Etani M, Kobayashi S, Takeda H. [The effect of immunotherapy and hyperthermia on patients with advanced or recurrent breast cancer]. Gan To Kagaku Ryoho 2013; 40:1596-9; PMID:24393860
   PubMedGoogle Scholar
• Liu J, Li J, Fan Y, Chang K, Yang X, Zhu W, Wu X, Pang Y. Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases. Ir J Med Sci 2014; PMID:24876093
   PubMedGoogle Scholar
• Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595
   PubMed Web of Science ®Google Scholar
• Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Eric T, Laurence Z, Guido K, Lorenzo G. Trial watch: radioimmunotherapy for oncological indications. Oncoimmunology 2014; DOI: 10.4161/21624011.2014.954929
   Google Scholar
• Reichenbach DK, Finn OJ. Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology 2013; 2:e23429; PMID:23802084; http://dx.doi.org/10.4161/onci.23429
   PubMedGoogle Scholar
• Wang Z, Hall MD, Rewers-Felkins KA, Quinlin IS, Wright SE. Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer. Oncoimmunology 2013; 2:e23335; PMID:23526065; http://dx.doi.org/10.4161/onci.23335
   PubMedGoogle Scholar
• Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014; 3:e28780; PMID:25083318; http://dx.doi.org/10.4161/onci.28780
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Dhodapkar KM. Recent advances and new opportunities for targeting human dendritic cells in situ. Oncoimmunology 2014; 3(8); DOI: 10.4161/21624011.2014.954832
   Google Scholar
• Dubrot J, Duraes FV, Potin L, Capotosti F, Brighouse D, Suter T, LeibundGut-Landmann S, Garbi N, Reith W, Swartz MA et al. Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4(+) T cell tolerance. J Exp Med 2014; 211:1153-66; PMID:24842370; http://dx.doi.org/10.1084/jem.20132000
   PubMed Web of Science ®Google Scholar
• Arora P, Baena A, Yu KO, Saini NK, Kharkwal SS, Goldberg MF, Kunnath-Velayudhan S, Carreño LJ, Venkataswamy MM, Kim J et al. A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 2014; 40:105-16; PMID:24412610; http://dx.doi.org/10.1016/j.immuni.2013.12.004
   PubMed Web of Science ®Google Scholar
• Schraml BU, van Blijswijk J, Zelenay S, Whitney PG, Filby A, Acton SE, Rogers NC, Moncaut N, Carvajal JJ, Reis e Sousa C. Genetic tracing via DNGR-1 expression history defines dendritic cells as a hematopoietic lineage. Cell 2013; 154:843-58; PMID:23953115; http://dx.doi.org/10.1016/j.cell.2013.07.014
   PubMedGoogle Scholar
• Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Scott CD, Hall JA et al. Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. J Exp Med 2013; 210:1961-76; PMID:23999499; http://dx.doi.org/10.1084/jem.20122508
   PubMed Web of Science ®Google Scholar
• Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, Zlobec I, Karamitopoulou E, Stachler MD, Odze RD et al. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity 2013; 39:1095-107; PMID:24290911; http://dx.doi.org/10.1016/j.immuni.2013.11.003
   PubMed Web of Science ®Google Scholar
• Muller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res 2014; 2:741-55; PMID:24916470; http://dx.doi.org/10.1158/2326-6066.CIR-13-0198
   PubMed Web of Science ®Google Scholar
• Baghdadi M, Yoneda A, Yamashina T, Nagao H, Komohara Y, Nagai S, Akiba H, Foretz M, Yoshiyama H, Kinoshita I et al. TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Immunity 2013; 39:1070-81; PMID:24315994; http://dx.doi.org/10.1016/j.immuni.2013.09.014
   PubMed Web of Science ®Google Scholar
• Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, Sykacek P, Frank L, Schramek D, Komnenovic V et al. A dual role for autophagy in a murine model of lung cancer. Nat Commun 2014; 5:3056; PMID:24445999; http://dx.doi.org/10.1038/ncomms4056
   PubMed Web of Science ®Google Scholar
• Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013; 27:1447-61; PMID:23824538; http://dx.doi.org/10.1101/gad.219642.113
   PubMed Web of Science ®Google Scholar
• Rosenfeldt MT, O’Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013; 504:296-300; PMID:24305049; http://dx.doi.org/10.1038/nature12865
   PubMed Web of Science ®Google Scholar
• Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011; 333:1109-12; PMID:21868666; http://dx.doi.org/10.1126/science.1201940
   PubMed Web of Science ®Google Scholar
• Ko A, Kanehisa A, Martins I, Senovilla L, Chargari C, Dugue D, Mariño G, Kepp O, Michaud M, Perfettini JL et al. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ 2014; 21:92-9; PMID:24037090; http://dx.doi.org/10.1038/cdd.2013.124
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on cell death 2012. Cell Death Differ 2012; 19:107-20; PMID:21760595; http://dx.doi.org/10.1038/cdd.2011.96
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015: in press; PMID:25236395; http://dx.doi.org/10.1038/cdd.2014.137
   PubMed Web of Science ®Google Scholar
• Garg AD, Dudek AM, Agostinis P. Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity. Oncoimmunology 2013; 2:e26260; PMID:24353910; http://dx.doi.org/10.4161/onci.26260
   PubMed Web of Science ®Google Scholar
• Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2013; 2:e24568; PMID:23894718; http://dx.doi.org/10.4161/onci.24568
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Zitvogel L. Immunological effects of chemotherapy in spontaneous breast cancers. Oncoimmunology 2013; 2:e27158; PMID:24498568; http://dx.doi.org/10.4161/onci.27158
   PubMedGoogle Scholar
• Mortenson ED, Fu YX. Anti-HER2Neu passive-aggressive immunotherapy. Oncoimmunology 2014; 3:e27296; PMID:24605268; http://dx.doi.org/10.4161/onci.27296
   PubMedGoogle Scholar
• Moschovi M, Alexiou GA, Patereli A, Stefanaki K, Doussis-Anagnostopoulou I, Stofas A, Sfakianos G, Prodromou N. Prognostic significance of cyclin A and B1 in pediatric embryonal tumors. J Neurooncol 2011; 103:699-704; PMID:21069428; http://dx.doi.org/10.1007/s11060-010-0451-y
   PubMedGoogle Scholar
• Andersen RS, Sorensen RB, Ritter C, Svane IM, Becker JC, thor Straten P, Andersen MH. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer Immunol Immunother 2011; 60:227-34; PMID:20981424; http://dx.doi.org/10.1007/s00262-010-0933-y
   PubMedGoogle Scholar
• Tyler EM, Koehne G. The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft-vs.- myeloma effect. Oncoimmunology 2013; 2:e24963; PMID:24073375; http://dx.doi.org/10.4161/onci.24963
   PubMed Web of Science ®Google Scholar
• Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep 2012; 28:1301-8; PMID:22895640
   PubMed Web of Science ®Google Scholar
• Tsurumi C, Esser N, Firat E, Gaedicke S, Follo M, Behe M, Elsässer-Beile U, Grosu AL, Graeser R, Niedermann G. Non-invasive in vivo imaging of tumor-associated CD133prominin. PLoS One 2010; 5:e15605; PMID:21187924; http://dx.doi.org/10.1371/journal.pone.0015605
   PubMedGoogle Scholar
• Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol 2014; 14:546-58; PMID:25060580; http://dx.doi.org/10.1038/nri3713
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7:179-90; PMID:17318230; http://dx.doi.org/10.1038/nri2038
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-84; PMID:16763660; http://dx.doi.org/10.1038/nrd2059
   PubMed Web of Science ®Google Scholar
• Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancertestis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5:615-25; PMID:16034368; http://dx.doi.org/10.1038/nrc1669
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Herve Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G et al. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014; 3:e28344; PMID:25050207; http://dx.doi.org/10.4161/onci.28344
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013; 13:525-41; PMID:23880905; http://dx.doi.org/10.1038/nrc3565
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355
   PubMed Web of Science ®Google Scholar
• Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9:167-81; PMID:19238149; http://dx.doi.org/10.1038/nrc2583
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265; http://dx.doi.org/10.4161/onci.27048
   PubMed Web of Science ®Google Scholar
• Bevacizumab in ovarian cancer. Nat Rev Cancer 2012; 12:83; PMID:22270952; http://dx.doi.org/10.1038/nrc3213
   PubMedGoogle Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx.doi.org/10.4161/onci.24850
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy–revisited. Nat Rev Drug Discov 2011; 10:591-600; PMID:21804596; http://dx.doi.org/10.1038/nrd3500
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370:709-22; PMID:24552318; http://dx.doi.org/10.1056/NEJMoa1308345
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Chen G, Han G, Shen B, Li Y. GM-CSF facilitates the development of inflammation-associated colorectal carcinoma. Oncoimmunology 2014; 3:e28186; PMID:24778929; http://dx.doi.org/10.4161/onci.28186
   PubMedGoogle Scholar
• Obermajer N, Kalinski P. Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells. Oncoimmunology 2012; 1:762-4; PMID:22934275; http://dx.doi.org/10.4161/onci.19681
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433-42; PMID:11496855; http://dx.doi.org/10.1056/NEJM200108093450607
   PubMed Web of Science ®Google Scholar
• Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. Oncoimmunology 2013; 2:e24677; PMID:23894722; http://dx.doi.org/10.4161/onci.23187
   PubMedGoogle Scholar
• Sharma S, Zhu L, Davoodi M, Harris-White M, Lee JM, St John M, Salgia R, Dubinett S. TLR3 agonists and proinflammatory antitumor activities. Expert Opin Ther Targets 2013; 17:481-3; PMID:23506058; http://dx.doi.org/10.1517/14728222.2013.781585
   PubMed Web of Science ®Google Scholar
• Nicodemus CF, Berek JS. TLR3 agonists as immunotherapeutic agents. Immunotherapy 2010; 2:137-40; PMID:20635920; http://dx.doi.org/10.2217/imt.10.8
   PubMed Web of Science ®Google Scholar
• Gujar SA, Clements D, Lee PW. Two is better than one: complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. Oncoimmunology 2014; 3:e27622; PMID:24804161; http://dx.doi.org/10.4161/onci.27622
   PubMed Web of Science ®Google Scholar
• Waldron TJ, Quatromoni JG, Karakasheva TA, Singhal S, Rustgi AK. Myeloid derived suppressor cells: targets for therapy. Oncoimmunology 2013; 2:e24117; PMID:23734336; http://dx.doi.org/10.4161/onci.24117
   PubMed Web of Science ®Google Scholar
• Hotz C, Bourquin C. Systemic cancer immunotherapy with Toll-like receptor 7 agonists: timing is everything. Oncoimmunology 2012; 1:227-8; PMID:22720251; http://dx.doi.org/10.4161/onci.1.2.18169
   PubMed Web of Science ®Google Scholar
• Demaria S, Vanpouille-Box C, Formenti SC, Adams S. The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology 2013; 2:e25997; PMID:24404422; http://dx.doi.org/10.4161/onci.25997
   PubMed Web of Science ®Google Scholar
• Li ZJ, Sohn KC, Choi DK, Shi G, Hong D, Lee HE, Whang KU, Lee YH, Im M, Lee Y et al. Roles of TLR7 in activation of NF-kappaB signaling of keratinocytes by imiquimod. PLoS One 2013; 8:e77159; PMID:24146965; http://dx.doi.org/10.1371/journal.pone.0077159
   PubMedGoogle Scholar
• Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology 2012; 1:1661-3; PMID:23264929; http://dx.doi.org/10.4161/onci.22033
   PubMed Web of Science ®Google Scholar
• Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122:575-85; PMID:22251703; http://dx.doi.org/10.1172/JCI61034
   PubMed Web of Science ®Google Scholar
• Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology 2013; 2:e27010; PMID:24498547; http://dx.doi.org/10.4161/onci.27010
   PubMed Web of Science ®Google Scholar
• Suri A, Saini S, Sinha A, Agarwal S, Verma A, Parashar D, Singh S, Gupta N, Jagadish N. Cancer testis antigens: a new paradigm for cancer therapy. Oncoimmunology 2012; 1:1194-6; PMID:23170277; http://dx.doi.org/10.4161/onci.20686
   PubMed Web of Science ®Google Scholar
• Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH. Cancertestis antigens and urological malignancies. Nat Rev Urol 2012; 9:386-96; PMID:22710665; http://dx.doi.org/10.1038/nrurol.2012.117
   PubMedGoogle Scholar
• Sznurkowski JJ, Zawrocki A, Karczewska J, Emerich J, Biernat W. Should we consider cancertestis antigens NY-ESO-1, MAGE-A4 and MAGE-A1 as potential targets for immunotherapy in vulvar squamous cell carcinoma? Histopathology 2011; 58:481-3; PMID:21323970; http://dx.doi.org/10.1111/j.1365-2559.2011.03772.x
   PubMedGoogle Scholar
• Turksma AW, Bontkes HJ, Ruizendaal JJ, Scholten KB, Akershoek J, Rampersad S, Moesbergen LM, Cillessen SA, Santegoets SJ, de Gruijl TD et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med 2013; 11:152; PMID:23787039; http://dx.doi.org/10.1186/1479-5876-11-152
   PubMedGoogle Scholar
• Manuel ER, Blache CA, Ellenhorn JD, Diamond DJ. Survivin the battle against immunosuppression. Oncoimmunology 2012; 1:240-1; PMID:22720256; http://dx.doi.org/10.4161/onci.1.2.18180
   PubMed Web of Science ®Google Scholar
• Altieri DC. Targeting survivin in cancer. Cancer Lett 2013; 332:225-8; PMID:22410464; http://dx.doi.org/10.1016/j.canlet.2012.03.005
   PubMed Web of Science ®Google Scholar
• Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med 2013; 11:83; PMID:23536996; http://dx.doi.org/10.1186/1479-5876-11-83
   PubMed Web of Science ®Google Scholar
• Rutella S, Locatelli F. Is there a role for cytokine-induced killer cells in cancer immunotherapy? Immunotherapy 2012; 4:867-9; PMID:23046228; http://dx.doi.org/10.2217/imt.12.89
   PubMedGoogle Scholar
• Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011; 2:363-8; PMID:21716717; http://dx.doi.org/10.7150/jca.2.363
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/; http://dx.doi.org/10.4161/onci.24238
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi.org/10.4161/onci.19549
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2:e23033; PMID:23483678; http://dx.doi.org/10.4161/onci.23033
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ. Enzalutamide–a major advance in the treatment of metastatic prostate cancer. N Engl J Med 2012; 367:1256-7; PMID:23013078; http://dx.doi.org/10.1056/NEJMe1209041
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-97; PMID:22894553; http://dx.doi.org/10.1056/NEJMoa1207506
   PubMed Web of Science ®Google Scholar
• Raymond E, Dalgleish A, Damber JE, Smith M, Pili R. Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol 2014; 73:1-8; PMID:24162378; http://dx.doi.org/10.1007/s00280-013-2321-8
   PubMed Web of Science ®Google Scholar
• Osanto S, van Poppel H, Burggraaf J. Tasquinimod: a novel drug in advanced prostate cancer. Future Oncol 2013; 9:1271-81; PMID:23980674; http://dx.doi.org/10.2217/fon.13.136
   PubMedGoogle Scholar
• George S, Pili R. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer. Curr Oncol Rep 2013; 15:65-8; PMID:23334511; http://dx.doi.org/10.1007/s11912-013-0295-7
   PubMed Web of Science ®Google Scholar
• Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC et al. Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR NK cell levels correlate with disease outcome. Oncoimmunology 2013; 2:e23080; PMID:23525357; http://dx.doi.org/10.4161/onci.23080
   PubMed Web of Science ®Google Scholar
• Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC et al. Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. Oncoimmunology 2013; 2:e23079; PMID:23525192; http://dx.doi.org/10.4161/onci.23079
   PubMedGoogle Scholar
• Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2:e26527; PMID:24404423; http://dx.doi.org/10.4161/onci.26527
   PubMed Web of Science ®Google Scholar
• Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012; 366:2008-16; PMID:22621628; http://dx.doi.org/10.1056/NEJMct1114348
   PubMed Web of Science ®Google Scholar
• Riedmann EM. CDX-1401 combined with TLR agonist: positive phase 1 results. Hum Vaccin Immunother 2012; 8:1742
   Web of Science ®Google Scholar
• Riediger C, Wingender G, Knolle P, Aulmann S, Stremmel W, Encke J. Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALBc mouse model. J Cancer Res Clin Oncol 2013; 139:2097-110; PMID:24114287; http://dx.doi.org/10.1007/s00432-013-1532-z
   PubMed Web of Science ®Google Scholar
• Valaperti A, Nishii M, Germano D, Liu PP, Eriksson U. Vaccination with Flt3L-induced CD8alpha+ dendritic cells prevents CD4+ T helper cell-mediated experimental autoimmune myocarditis. Vaccine 2013; 31:4802-11; PMID:23948227; http://dx.doi.org/10.1016/j.vaccine.2013.07.084
   PubMedGoogle Scholar
• Kretz-Rommel A, Qin F, Dakappagari N, Torensma R, Faas S, Wu D, Bowdish KS. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother 2007; 30:715-26; PMID:17893564; http://dx.doi.org/10.1097/CJI.0b013e318135472c
   PubMed Web of Science ®Google Scholar
• Pereira CF, Torensma R, Hebeda K, Kretz-Rommel A, Faas SJ, Figdor CG, Adema GJ. In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model. J Immunother 2007; 30:705-14; PMID:17893563; http://dx.doi.org/10.1097/CJI.0b013e31812e6256
   PubMedGoogle Scholar
• Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G et al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 2013; 36:152-7; PMID:23377664; http://dx.doi.org/10.1097/CJI.0b013e3182811ae4
   PubMed Web of Science ®Google Scholar
• Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, De Rosa N, Pickett N, Mosca PJ, Burchette J et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 2013; 123:3135-45; PMID:23934126; http://dx.doi.org/10.1172/JCI67544
   PubMed Web of Science ®Google Scholar